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Abstract In covariate (sub)models of population pharma-
cokinetic models, most covariates are normalized to the
median value; however, for body weight, normalization to
70 kg or 1 kg is often applied. In this article, we illustrate
the impact of normalization weight on the precision of
population clearance (CLpop) parameter estimates. The
influence of normalization weight (70, 1 kg or median
weight) on the precision of the CLpop estimate, expressed
as relative standard error (RSE), was illustrated using data
from a pharmacokinetic study in neonates with a median
weight of 2.7 kg. In addition, a simulation study was per-
formed to show the impact of normalization to 70 kg in
pharmacokinetic studies with paediatric or obese patients.
The RSE of the CLpop parameter estimate in the neonatal
dataset was lowest with normalization to median weight
(8.1%), compared with normalization to 1 kg (10.5%) or
70 kg (48.8%). Typical clearance (CL) predictions were
independent of the normalization weight used. Simulations
showed that the increase in RSE of the CLpop estimate with
70 kg normalization was highest in studies with a narrow
weight range and a geometric mean weight away from
70 kg. When, instead of normalizing with median weight, a
weight outside the observed range is used, the RSE of the
CLpop estimate will be inflated, and should therefore not be
used for model selection. Instead, established mathematical
principles can be used to calculate the RSE of the typical
CL (CLTV) at a relevant weight to evaluate the precision of
CL predictions.
Key Points
Normalization to a weight outside the observed
weight range (e.g. 70 kg normalization in a
paediatric study) can increase the uncertainty of
parameter estimates in pharmacokinetic covariate
models.
The predictive performance of pharmacokinetic
models and their covariate submodels is unaffected
by weight normalization.
When normalizing outside the observed covariate
range, the RSEs of the corresponding population
estimates should generally not be used for model
evaluation. The RSE of the typical parameter at a
relevant covariate value can be used instead.
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1 Introduction
In population pharmacokinetic modelling, covariate mod-
els are built to describe between-subject variability in
pharmacokinetic parameters (e.g. clearance [CL]) based on
patient information (e.g. weight) [1, 2]. These covariate
models can then be used to support personalized pharma-
cotherapy [3]. One of the most commonly identified
covariates in population pharmacokinetic models is the
body weight of the patient [4–8]. The relationship between
drug CL and weight is often described using a power
function:
CLTV ¼ CLpop  WTi
WTnorm
 EXPWT
ð1Þ
CLi ¼ CLTV  eETAi; ð2Þ
where CLTV represents the predicted CL for a typical
individual with weight equal to WTi, CLpop represents the
population estimate of CL for an individual with a weight
equal to the normalization weight (WTnorm), WTi repre-
sents the individual’s weight, EXPWT represents the
exponent that characterizes the influence of weight on CL,
CLi represents the individual post hoc predictions of CL for
individual i, and eETA represents the post hoc estimate of
the deviation of individual i from the predicted CL of a
typical individual.
EXPWT in this weight-based Eq. 1 can be fixed a priori
(for instance to 1, 0.75 or 0.67) or estimated [9–12]. For
continuous covariates other than weight, it is common to
normalize to the mean or the median covariate value of the
covariate in the dataset, whereas for weight, normalization
to 70 kg is often chosen [2, 13–15]. The rationale for this
approach is that the estimate of CLpop will then represent
the value of a typical 70 kg adult, which can easily be
compared with other (adult) studies [2, 5, 10]. For similar
reasons, a WTnorm of 1 kg can be chosen or, when no
explicit normalization is performed, this normalization is
implicitly chosen [9]. Recently, Mahmood and Tegenge
investigated the impact of 70 and 1 kg weight normaliza-
tion on CLTV predictions and concluded that weight nor-
malization has no impact on CLTV predictions [9].
The concept of normalization has been extensively
studied in linear regression [16, 17]. When normalizing the
data to the mean, the relative standard error (RSE) of the
intercept term is minimized, while normalizing outside of
the data range can result in estimates with poor precision
[16]. In this context, the power function in Eq. 1 can be
considered a linear model in the log domain, with an
intercept of log CLpop [13]. If the same concepts apply, we
might expect the RSE of the estimate of CLpop to be
minimal when normalizing weight to the geometric mean.
Alternatively, normalizing to 1 kg or 70 kg might result in
high RSE of CLpop, especially in populations with high or
low weights.
As the impact of 70 kg normalization on the RSE of
CLpop could be considerable, especially when analysing
data from neonatal or morbidly obese patients, insight into
the statistical consequences of the selected normalization
weight seems important among those involved in popula-
tion pharmacokinetic modelling. In this article, we provide
mathematical derivations of the phenomena and illustrate
the impact of weight normalization on the precision of the
parameter estimate of CLpop. For this, we used an existing
neonatal pharmacokinetic dataset, as well as simulated data
of various paediatric and obese populations.
2 Methods
2.1 Case Study
A dataset from a previously published population phar-
macokinetic analysis of phenobarbital in term and preterm
neonates was used [18]. This dataset contained phenobar-
bital plasma concentrations collected during therapeutic
drug monitoring from 53 neonates up to 80 h after the last
phenobarbital dose. The weight of these neonates ranged
from 0.45 to 4.5 kg and had a median value of 2.7 kg [18].
These data were modelled using a one-compartment
model with interindividual variability on CL and volume of
distribution (V) and a proportional error model. The
covariate model consisted of a linear model (exponent
fixed to a value of 1) for weight on V and a power model
with an estimated exponent for weight on CL (Eq. 1). For
three different values of WTnorm (1, 2.7, and 70 kg),
parameter estimates were obtained using NONMEM 7.3
[19]. The collinearity of the parameter estimates was
assessed using the condition number, which is defined as
the square root of the ratio between the largest and smallest
eigenvalue of the correlation matrix. RSEs of the parameter
estimates (i.e., CLpop and EXPWT) in NONMEM were
obtained using two different methods: calculation from the
estimated variance–covariance matrix in NONMEM, and
calculation calculated from 1000 bootstrap runs, which
were performed using PsN 4.2.0. for each of the three
models [20].
Furthermore, from these 1000 bootstrap runs, the esti-
mates of CLpop and EXPWT (see Eq. 1) were used to cal-
culate the predicted function of CLTV over weight for each
of the bootstrap runs over a weight range of 0.5–200 kg.
For each of the three weight-normalized models, we used
these functions of CLTV over weight to obtain the 95%
confidence interval and RSE of CLTV predictions over the
weight range of 0.5–200 kg for all three values of WTnorm.
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RSE of CLTV predictions over weight were also calcu-
lated using the variance–covariance matrix obtained from
NONMEM [13]. For this, we log-transformed the power
function of Eq. 1, which resulted in the following linear
model:
Log CLTV ¼ LogCLpop þ EXPWT  log
WTi
WTnorm
 
; ð3Þ
where LogCLpop represents the estimate of the natural
logarithm of CL of an individual whose weight is equal to
the normalization weight. With a linear model, we can use
principles from linear regression to calculate the RSE of
the predictions of CLTV at an arbitrary weight WTi:
VAR Log CLTVð Þ ¼ VARLogCLpop þ 2
 COVARLogCLpop;EXPwt
 log WTi
WTnorm
 
þ VAREXPwt
 log WTi
WTnorm
  2
ð4Þ
RSE CLTVð Þ ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
eVARðLogCLTVÞ  1
p
; ð5Þ
where VARLogCLpop represents the variance of the estimate
of LogCLpop, COVARLogCLpop;EXPwt represents the covari-
ance between the estimates for LogCLpop and EXPWT, and
VAREXPwt represents the variance of the estimate of
EXPWT. Mathematical derivation of Eqs. 4 and 5 are
supplied in the electronic supplementary material.
2.2 Impact of WTnorm on the Relative Standard
Error of CLpop for Different Weight
Distributions
To further study the impact of WTnorm in a covariate
function on the RSE of the estimate of CLpop with different
weight distributions, we generated pharmacokinetic data-
sets of patient populations with six different weight dis-
tributions in R version 3.3.2. We then fitted a one-
compartmental pharmacokinetic model described in the
previous subsection, re-estimating all parameters.
For this purpose, three paediatric weight distributions
(PEDIAT1, PEDIAT2 and PEDIAT3) and three weight
distributions of adult populations including obese patients
(OBESE1, OBESE2 and OBESE3) were used to generate
simulated datasets (Table 2).
For each weight distribution, 250 datasets consisting of
50 patients were randomly sampled from the distributions
using R software. For each patient, concentrations were
simulated for 24, 72 and 120 h after a single 10 mg/kg
dose. The simulated datasets were fitted with the models
described in Sect. 2.1 and weight was normalized to either
70 kg or the expected geometric mean of the weight
distribution. Geometric mean was chosen as we hypothe-
sized that this would result in the minimum RSE of CLpop,
as discussed in the Introduction. The proportion of suc-
cessful covariance steps was compared for a statistically
significant difference between the different normalization
strategies, using a two-sample test for equality of propor-
tions with continuity correction (prop.test function in R).
For datasets that yielded successful covariance steps in
both model fits, we calculated the ratio of the RSEs for the
estimate of CLpop of both model fits:
RSE ratio ¼ RSE CLpop70 kg normalization
RSE CLpop Geometric mean normalization
ð6Þ
3 Results
3.1 Case Study
Table 1 shows that only the RSE of the estimate of CLpop
varied with normalization weight. Normalizing to median
weight (2.7 kg) resulted in a lower RSE of CLpop, com-
pared with 1 kg and 70 kg normalization. RSEs were 10.6,
8.0, and 48.2% for 1, 2.7 and 70 kg, respectively (Table 1).
These RSE values were obtained from NONMEM’s
covariance step, but similar results were obtained using a
bootstrap (1 kg: 10.5%; 2.7 kg: 8.1%; 70 kg: 48.8%).
Additionally, there was a stronger correlation between the
uncertainty of the parameter estimates of CLpop and
EXPWT when normalizing to 1 kg or 70 kg (Table 1).
Finally, increased collinearity between the parameters was
observed for the 1 kg and 70 kg normalizations, as iden-
tified by a higher condition number (Table 1).
The parameter estimates of CLpop varied with normal-
ization weight (Table 1), which results from the fact that
this parameter represents the typical CL of a subject whose
weight is equal to the normalization weight. However, the
same predicted CLTV (Eq. 1) is obtained for the three
model fits with different normalization weights since
CLTV ¼ 0:00615  WTi
1kg
 0:665
 0:0119  WTi
2:7kg
 0:665
 0:104  WTi
70kg
 0:665
This is further illustrated by Fig. 1 where the results on
predicted CLTV for the model with a normalization weight
of 2.7 kg is shown, while the models with different
normalization weights produced equivalent results.
Additionally, Fig. 1a shows that the 95% bootstrap
confidence interval of predicted CLTV broadens the
further the weight moves away from the centre of the
weight distribution of the patient population in the dataset.
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Figure 1b illustrates that the CLTV functions from different
bootstrap samples are very similar within the range of the
data, and diverge outside the weight range of the original
dataset, explaining the broader confidence intervals seen in
Fig. 1a.
Figure 2 shows the RSE of the predicted function of
CLTV over weight, as well as the RSE of the estimate of the
parameter CLpop. The RSE of the CLTV function was cal-
culated using either bootstrap or the variance–covariance
matrix (Eq. 5), with both methods resulting in similar
results (Fig. 2). Using Eq. 5, the minimum RSE of CLTV
(5.8%) was calculated at 1.9 kg, which is close to, but not
equal to, measures of the central tendency of the weight
distribution, such as the mean (2.4 kg, RSE = 6.6%),
median (2.7 kg, RSE = 7.5%) or geometric mean (2.1 kg,
RSE = 6.0%). The RSE of the estimate of the CLpop
parameter reported by NONMEM for a model with a given
normalization weight matches the RSE of the CLTV func-
tion at the normalization weight. The former results in
6.4% RSE with 1.9 kg normalization, and 8.0% RSE with
normalization to the median.
3.2 Impact of 70 kg Normalization in Different
Paediatric and Obese Populations
Evaluation of the impact of 70 kg normalization on the
RSE of CLpop estimates for simulated paediatric and obese
datasets with various weight distributions showed that,
generally, 70 kg normalization resulted in a higher RSE of
the CLpop estimate compared with normalization to geo-
metric mean weight, resulting in an RSE ratio above 1
(Table 2, Fig. 3). The results show that the degree of
impact of 70 kg normalization depends on the weight
distribution in the dataset. The three paediatric weight
distributions had a geometric mean weight of 20 kg, but
different dispersion around the geometric mean. The RSE
ratio was highest (median RSE ratio = 4.3) for the log-
normal distribution with a standard deviation on the loga-
rithmic scale of 0.25 (PEDIAT1).
Table 1 Parameter estimates
and relative standard errors (%)
from the NONMEM covariance
step for the neonatal dataset
using different normalization
weights
WTnorm 1 kg 2.7 kg (median) 70 kg
OFV 1091 1091 1091
CLpop (L/h) 0.00615 (10.6%) 0.0119 (8.0%) 0.104 (48.2%)
V (L) 2.37 (4.4%) 2.37 (4.4%) 2.37 (4.4%)
EXPWT 0.665 (20.3%) 0.665 (20.3%) 0.665 (20.3%)
Proportional error [%] 2.89 (23.5%) 2.89 (23.5%) 2.89 (23.5%)
Condition number 4.4 2.8 16.2
CorrelationCLpop, EXPwt
a - 0.840 0.545 0.988
aCorrelation of the uncertainty of the parameter estimates of CLpop and EXPWT
OFV objective function value, CLpop typical clearance of subject whose weight is equal to normalization
weight, V volume of distribution, EXPWT exponent in Eq. 1, WTnorm normalization weight in Eq. 1
Fig. 1 Clearance predictions versus weight (0.5–200 kg) in an
example neonatal dataset. (a) Median (solid black line) and 95%
confidence interval (dotted line) of 1000 functions of CLTV versus
weight obtained from 1000 bootstrap runs; green dots represent the
individual post hoc CLi estimates of the studied patients. (b) Estimated
function of CLTV versus weight from the original dataset (solid black
line) and illustrative set of functions of CLTV versus weight (grey
solid lines) obtained in six (of 1000) separate bootstrap runs; green
dots represent the individual post hoc CLi estimates of patients in the
original dataset. Depicted results were obtained using a normalization
weight of 2.7 kg. CLTV clearance for a typical individual, CLi
clearance for individual i
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The weight distributions of OBESE1 and OBESE2 have
a similar standard deviation on a logarithmic scale, but
different geometric means of the weight (162 and 118 kg,
respectively). The results in Table 2 and Fig. 3 show that
this results in a lower RSE ratio in OBESE2, compared
with OBESE1 (median RSE ratio of 2.3 and 3.5,
respectively). Normalizing to 70 kg has only marginal
impact on RSE in OBESE3 (median RSE ratio = 1.1), with
a geometric mean that is closer to 70 kg than OBESE2
(97 kg vs. 118 kg), as well as a higher standard deviation
on a logarithmic scale (0.35 vs. 0.2).
Table 2 shows that for both paediatric and adult popu-
lations, the impact of 70 kg normalization on the RSE of
the estimate of CLpop was highest for studies with a narrow
weight range (low standard deviation on a logarithmic
scale) and a median weight away from 70 kg.
The percentage of datasets for which a successful
covariance step could be obtained in both model fits ranged
from 28 to 84% in the different scenarios. The proportion
of successful covariance steps was significantly higher
using geometric mean normalization compared with 70 kg
normalization in scenarios PEDIAT1 (p\ 0.001) and
PEDIAT2 (p\ 0.001), but not in any of the other sce-
narios. The most common cause of the missing covariance
steps was boundary issues due to the difficulty in esti-
mating the variance for the interindividual variability of
CL.
4 Discussion
This report illustrates the statistical principle that, when
estimating the exponent in a body weight-based covariate
submodel of a population pharmacokinetic model (Eq. 1),
Fig. 2 Relation between weight and the RSE of both CLTV and
CLpop in an illustrative neonatal dataset. The solid line represents the
RSE of CLTV predictions from 1000 bootstrap runs, the dotted line
represents the RSE of CLTV predictions obtained from the variance–
covariance matrix (Eq. 5), and the red dots represent the RSE of the
estimated CLpop parameter using the corresponding normalization
weight, obtained from the covariance step of a single NONMEM run.
The vertical tick marks on the bottom of the graph depict the body
weights of subjects in the dataset. RSE relative standard error, CLTV
clearance for a typical individual, CLpop population clearance
Table 2 Characteristics of the different weight distributions and summary of the simulation results
Distribution Geometric
mean (kg)
SD
on
log-
scale
Distance between
geometric mean and
70 kg (in SD on log-
scale)
Median RSE ratio
CLpop (Eq. 6) for
70 kg
normalization
Covariance step
successful with
70 kg
normalization (%)
Covariance step
successful with
geometric mean
normalization (%)
Covariate step
successful in
both
normalizations
(%)
PEDIAT1
Log-normal
20 0.25 5.0 4.3 72 57 54
PEDIAT2
Uniform
10–32 kg
20 0.33 3.9 3.5 79 63 59
PEDIAT3
Uniform
1–51 kg
20 0.83 1.5 1.7 85 85 84
OBESE1
Uniform
110–220
162 0.2 - 4.2 3.5 31 32 28
OBESE2
Uniform
80–160
118 0.2 - 2.6 2.3 47 48 45
OBESE3
Uniform
45–160
97 0.35 - 0.9 1.1 52 53 50
RSE relative standard error, SD standard deviation, CLpop population clearance
Influence of Normalization Weight in Population PK Covariate Models
the use of a normalization weight outside the observed
weight range can result in an inflated RSE of the estimate
of CLpop. This holds true for 70 kg normalization, but also
for 1 kg normalization (which is sometimes referred to as
‘no normalization’) [9].
The RSE of the CL parameter CLpop represents the RSE
of the predicted typical CL (CLTV) at a particular nor-
malization weight, and is therefore not a universal measure
for the precision of the estimate of CL (Table 2). As we
show, the RSE of the predicted CLTV is not constant, but
dependent on the weight of the subject for whom CLTV is
predicted (Figs. 1 and 2). This means that the RSE of
CLpop represents how precisely CL can be estimated for a
subject at the applied normalization weight. When esti-
mating CLpop at a normalization weight outside the
observed weight range, the RSE of CLpop will be inflated
and cannot be used as a criterion for model selection. Our
example with 70 kg normalization in a neonatal pharma-
cokinetic model showed, for instance, that the RSE of the
CLpop estimate increased sixfold compared with the esti-
mate obtained with normalization to the median.
In linear regression, the minimum RSE is obtained by
normalizing to the mean value. Because the power function
becomes a linear model in the log domain, one might
expect the minimum RSE at the geometric mean weight as
this is equivalent to normalizing to the mean value of log of
weight. The results of the case study show that this is not
necessarily the case for covariate models of non-linear
mixed-effects models. In our case study, we found that the
minimum RSE of CLpop was obtained by normalizing to
1.9 kg, rather than the mean, median or geometric mean
weight. The normalization weight with minimum RSE of
CLpop can be predicted by minimizing Eq. 5, although this
does require that an initial model with a test normalization
weight is run to obtain an estimate of the variance–co-
variance matrix. In our case study, we normalized to the
median weight as this is the most commonly used nor-
malization weight. This increased the RSE of CLpop to
8.0%, from the minimum RSE of 6.4% at a normalization
weight of 1.9 kg. However, normalizing to the median
weight will likely be fit-for-purpose in most cases.
Regardless of the normalization weight that is used,
Eqs. 4 and 5 can be used to calculate RSE values for any
given body weight based on a variance–covariance matrix.
This can be useful as normalization to 70 kg as a ‘stan-
dardized individual’ is sometimes advocated to improve
comparisons of results from different studies [5]. In these
cases, normalization to 70 kg can applied and Eqs. 4 and 5
can be used to calculate the RSE values for a relevant body
weight to enable its use as a model selection criterion.
Alternatively, model estimation can be performed with
median weight normalization, and both the estimated
CLpop parameter for the median weight and the derived
CLTV for a 70 kg individual are reported, in which case the
calculated RSE of the latter is relevant when comparing
results from different studies.
The expected increase in RSE of centring to 70 kg is
dependent on both the variance of the weight distribution
and the distance of the mean of the distribution from the
chosen normalization weight (Fig. 3). The effect seems to
be largest in cases of narrow distributions with a mean
covariate value far away from the centre of the data. This
Fig. 3 RSE ratio of CLpop
(Eq. 6) when using 70 kg
normalization compared with
geometric mean weight
normalization. For each weight
distribution, 250 datasets were
generated and refitted. Only
results of datasets for which the
covariance step was successful
for both the 70 kg and
geometric mean weight
normalization were included in
this graph (Table 2). RSE
relative standard error, CLpop
population clearance
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especially holds true for (pre)term neonates, infants and
young children and (morbidly) obese patients. In cases
where the population mean is away from 70 kg but the
range of weights includes 70 kg (such as scenario
OBESE3), normalizing to 70 kg will likely result in an
RSE increase of CLpop that will not affect its application in
model selection (Fig. 3).
It is important to realize that weight normalization only
impacts the precision of the CLpop parameter estimate, in
case a covariate model according to Eq. 1 is chosen. If the
exponent is fixed, the RSE of the estimate of CLpop will be
unaffected by normalization weight. Similarly, in this sit-
uation, the RSE of the predicted CLTV will be independent
of the subject’s weight. Whether or not the exponent should
be estimated or fixed is an ongoing discussion that is out-
side the scope of this paper [5, 11, 12].
In the simulation study, the calculation of the RSE ratio
required that both model fits resulted in a successful
covariance step. This requirement introduces the potential
for selection bias as the results from the excluded datasets
might have had a different impact of normalization on the
RSE of CLpop. However, performing a bootstrap on each of
the 3000 model fits to obtain the RSE ratio independent of
covariance step success was not feasible due to its com-
putational demands.
Interestingly, the simulation study showed that in two of
the six simulated scenarios, a higher percentage of runs
with successful covariance steps was obtained when using
geometric mean normalization instead of 70 kg normal-
ization. Additionally, the paediatric case study showed that
with normalization outside the observed weight range,
collinearity between the CLpop and EXPWT parameter
estimates is increased (Table 1). This suggests that nor-
malization affects the stability of the parameter estimation
process, which has been described for both linear models,
as well as population pharmacokinetic models [15].
Although the increased stability was not observed in all
simulated scenarios, it might be a reason to advocate
median weight normalization over normalization outside
the observed weight range.
5 Conclusions
Normalizing body weight-based covariate relationships in
population pharmacokinetic models to 1 kg or 70 kg can
inflate the RSE of the parameter estimate of CLpop in
population pharmacokinetic models. The predictive per-
formance of the models are unaffected by normalization.
However, when normalizing with a weight outside the
observed weight range, the CLpop RSE represents the
precision of the CLTV at this extrapolated weight, and this
value should therefore not be used for model selection.
Instead, the precision of CLTV at a relevant weight value
can be calculated from the covariance matrix.
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